Cleveland Clinic | Strategic Alliance Partners

Cleveland Clinic Cancer Institute provides complete cancer care enhanced by innovative basic, clinical and translational research. It offers the most effective techniques to achieve long-term survival and improve patients’ quality of life. Cleveland Clinic Cancer Institute’s more than 800 physicians, researchers, nurses and technicians care for thousands of patients each year and provide access to a wide range of clinical trials. Cleveland Clinic Cancer Institute has a global presence, uniting clinicians based in our Cancer Institute, Cleveland Clinic’s other patient-centered institutes, our regional hospitals and health centers, and our operations in Florida, London and Abu Dhabi. Cleveland Clinic is a nonprofit, multi-specialty academic medical center with more than 5,000 staff physicians and researchers who integrate outpatient and hospital care with research and education for better patient outcomes and experience. Cleveland Clinic is a trusted healthcare leader. We’re recognized in the U.S. and throughout the world for our expertise and care.

Be sure to tune into our Cancer Advances podcast where we explore the latest innovative research and clinical advances in the field of oncology. Listen now!

Connect with us:

Latest from Cleveland Clinic

Unmet Needs and Future Perspectives in Treatment of MDS

July 06, 2023

Video

Expert oncologists discuss unmet needs and share final thoughts on the future of treatment of patients with lower-risk MDS.

Treating HER2+ Breast Cancer with CNS Involvement

July 06, 2023

Video

Clinical insights on approaches to treating HER2+ metastatic breast cancer with central nervous system involvement.

Clinical Management of Patients with Lower-risk MDS

July 06, 2023

Video

Ralph Boccia, MD, FACP, highlights emerging therapies and the importance of next-generation sequencing for patients with MDS.

Updates from ASCO 2023 in HER2+ Metastatic Breast Cancer

July 06, 2023

Video

Megan Kruse, MD, reviews clinical trial data updates from the 2023 ASCO Annual Meeting on HER2+ metastatic breast cancer.

Emerging Therapies for Treatment of MDS

June 29, 2023

Video

Expert oncologists discuss management strategies for patients with lower-risk MDS considering upcoming treatment options.

Data Updates from SABCS 2022 in HER2+ Metastatic Breast Cancer

June 29, 2023

Video

An expert on HER2+ metastatic breast cancer reviews data from the DESTINY-Breast02 and DESTINY-Breast03 trials, which were updated at the 2022 San Antonio Breast Cancer Symposium.

Safety and Efficacy of Luspatercept in Frontline Setting in Patients with MDS

June 29, 2023

Video

Oncologists review study design and discuss key safety and efficacy data of the COMMANDS trial investigating luspatercept in frontline setting in patients with lower-risk MDS.

Evolving Treatment Strategies for HER2+ Metastatic Breast Cancer

June 29, 2023

Video

Megan Kruse, MD, discusses the evolving treatment landscape for patients with HER2+ metastatic breast cancer.

Dr Gupta on the MAIN-CAV Trial of Maintenance Cabozantinib Plus Avelumab in mUC

June 27, 2023

Video

Shilpa Gupta, MD, discusses the design, methodology, and potential significance of the ongoing phase 3 MAIN-CAV trial in patients with locally advanced/metastatic urothelial carcinoma

Clinical Use of Luspatercept on Patients with Lower-risk MDS

June 22, 2023

Video

Ralph Boccia, MD, FACP, shares his clinical experience using luspatercept to treat patient with lower-risk MDS.

Frontline Treatment Options for Lower-Risk MDS

June 22, 2023

Video

Expert oncologists discuss standard-of-care frontline treatments for patients with lower-risk MDS.

Dr Gupta on the 4-Year Efficacy of the EV-103 Trial in Urothelial Carcinoma

June 15, 2023

Video

Shilpa Gupta, MD, discusses the 4-year safety and efficacy data derived from the phase 1/2 EV-103 trial in patients with locally advanced or metastatic urothelial carcinoma.

Risk Stratification of Myelodysplastic Syndromes [MDS]

June 15, 2023

Video

Ralph Boccia, MD, FACP, and Hetty Carraway, MD, review Myelodysplastic Syndromes [MDS] risk stratification criteria used in their practices.

Enfortumab Vedotin Plus Pembrolizumab Produces Durable Responses, Safety in Metastatic Urothelial Carcinoma

June 05, 2023

Article

The combination of enfortumab vedotin-ejfv and pembrolizumab generated rapid and durable responses and demonstrated a manageable safety profile in patients with locally advanced or metastatic urothelial carcinoma who were ineligible for cisplatin.

Dr Gupta on Anticipated Real-world Benefit of the JAVELIN Bladder 100 Trial in Urothelial Carcinoma

June 02, 2023

Video

Shilpa Gupta, MD, discusses the real-world benefit that may be derived based on findings from the long-term analysis of the phase 3 JAVELIN Bladder 100 trial in patients with advanced urothelial carcinoma.

Clinical Updates for the Management of Lung Cancer Brain Metastases

May 25, 2023

Article

As improved cancer therapies are helping patients live longer, the safe and effective management of lung cancer brain metastases is coming to the fore.

Dr Gupta on the Background of the JAVELIN Bladder 100 Trial in Urothelial Carcinoma

May 18, 2023

Video

Shilpa Gupta, MD, discusses the background of the phase 3 JAVELIN Bladder 100 trial in patients with advanced urothelial carcinoma.

Novel Therapy in Urothelial Carcinoma: An Evolving Treatment Landscape

May 18, 2023

Video

Closing out their discussion on urothelial carcinoma, key opinion leaders share clinical pearls and excitement for the evolving treatment landscape.

Sequencing Later-Line Therapies for Metastatic Urothelial Carcinoma

May 18, 2023

Video

A brief review of second-line and subsequent treatment strategies in metastatic urothelial carcinoma and novel therapies being explored in this space.

Metastatic Urothelial Carcinoma: Intensifying Maintenance Immunotherapy

May 11, 2023

Video

Shared insight on clinical trial data behind the intensification of maintenance immunotherapy in patients with metastatic urothelial carcinoma.